The first-in-main trial for the personalised therapeutic human cancer vaccine is scheduled to begin in the first quarter of 2015. This has the potential to target a wide range of hard-to-treat cancers with a single product.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
